menu
    • menu

    Company profile for Parabilis Medicines

    NEW Drugs in Dev: 2
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Parabilis Medicines, formerly Fog Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing transformative therapies that address the limitations of existing treatments and aim to make a meaningful difference in patients’ lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Parabilis MedicinesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge Discovery Park 30 Acorn Park Drive, Cambridge, MA 02140
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://parabilismed.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/parabilis-medicines/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Parabilis IPO Follows Regeneron Deal Amid Rising IPO Listings
    Parabilis IPO Follows Regeneron Deal Amid Rising IPO Listings

    21 May 2026

    // ENDPOINTS

    https://endpoints.news/parabilis-reveals-ipo-plans-the-day-after-regeneron-deal-as-listings-heat-up/

    ENDPOINTS
    21 May 2026
    Share Share
    Regeneron reaches $125M Parabilis deal for hard-to-catch drug
    Regeneron reaches $125M Parabilis deal for hard-to-catch drug

    18 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/18/3296473/0/en/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas.html

    GLOBENEWSWIRE
    18 May 2026
    Share Share
    Parabilis Medicines Grows Its Executive Leadership Team
    Parabilis Medicines Grows Its Executive Leadership Team

    14 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260414928316/en/Parabilis-Medicines-Expands-Executive-Leadership-Team

    BUSINESSWIRE
    14 Apr 2026
    Share Share
    Parabilis Medicines Secures $305M Funding For FOG-001 Trials
    Parabilis Medicines Secures $305M Funding For FOG-001 Trials

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108088855/en/Parabilis-Medicines-Announces-Oversubscribed-%24305-Million-Financing-to-Support-Ongoing-FOG-001-zolucatetide-Clinical-Development-Across-a-Broad-Range-of-Tumors-and-Advance-Pioneering-Pipeline-and-Helicon-Platform

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Parabilis Medicines Showcases Positive Early Data
    Parabilis Medicines Showcases Positive Early Data

    21 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251121107097/en/Parabilis-Medicines-Highlights-Promising-Preliminary-Clinical-Results-in-Patients-with-Adamantinomatous-Craniopharyngioma-from-Ongoing-FOG-001-Clinical-Trial-at-SNO-2025

    BUSINESSWIRE
    21 Nov 2025
    Share Share
    Parabilis Medicines Secures FDA Fast Track for FOG-001
    Parabilis Medicines Secures FDA Fast Track for FOG-001

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112954263/en/Parabilis-Medicines-Receives-FDA-Fast-Track-Designation-for-FOG-001-the-First-and-Only-Direct-Inhibitor-of-the--cateninTCF-Interaction-for-the-Treatment-of-Desmoid-Tumors

    BUSINESSWIRE
    12 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search